GNOM News and Press, Global X Genomics & Biotechnology ETF From 12/20/19

With last recession ending over 10 years ago, investors are becoming more concerned for the inevitable "next one." While attempting to accurately time a recession can be a futile exercise, adequate preparation - through gaining knowledge of defensive or countercyclical investments and thoughtf...

By Ansh Chaudhary The ETF Deathwatch list remained the same size in October. Twenty-one exchange-traded products ("ETPs") were added to the list, and 21 funds were removed. Of the removals, 12 were removed due to increased health and nine were due to asset managers closing their funds. Oc...

At first glance, equity sectors appear to be relatively consistent over time. While the economy evolves, Consumer Discretionary companies are always there to help us spend our disposable income. Energy firms are always there to fuel our vehicles to get us from point A to point B. In fact, in r...

Aprea Therapeutics (NASDAQ: APRE ) opens for trading after raising the size of its IPO to 5.67M shares from 5M and pricing its IPO at $15 , the mid‐point of the $14‐$16 expected range. More news on: Aprea Therapeutics, Monopar Therapeutics, ADC Therapeutics SA, Healthcare st...

By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...

By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...

By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

By Andy Acker, CFA and Denny Fish Portfolio Managers Andy Acker and Denny Fish explore disruptive forces in healthcare and technology. Disruption is being felt across industries and geographies and proving to be a differentiator in the long-term performance of investors' portfolios. Su...